Alto Neuroscience stock holds Buy rating at Stifel despite mixed trial data

Alto Neuroscience (ANRO) reported mixed Phase 2 results for ALTO-203 in major depressive disorder, demonstrating reductions in a target EEG biomarker but failing to meet the primary mood scale endpoint. Stifel maintained its Buy rating, viewing the trial as exploratory and not thesis-impacting, despite observed improvements in attention and wakefulness. While the company shows rapid cash burn, it maintains strong liquidity and is advancing other pipeline assets, including the recently acquired ALTO-207 for treatment-resistant depression, indicating a broader strategic focus beyond this specific program.

Analysis

Alto Neuroscience (ANRO) reported mixed Phase 2 results for its ALTO-203 drug, successfully demonstrating a reduction in the target EEG biomarker but failing to meet its primary clinical endpoint on a mood scale. Stifel's decision to maintain its Buy rating and $10.00 price target suggests the trial was viewed as exploratory and not central to the investment thesis, a sentiment supported by the observation of improvements in sustained attention and wakefulness. The company's financial position reflects the typical profile of a clinical-stage biotech: a strong liquidity position indicated by a current ratio of 22.53, but counterbalanced by a rapid cash burn. The investment narrative for Alto is not solely dependent on ALTO-203; the company is actively advancing its pipeline through developments like the acquisition of ALTO-207 for treatment-resistant depression and positive tolerability data for ALTO-300, which is also linked to a specific EEG biomarker. The significant divergence in analyst price targets, ranging from $4 to $18, underscores the high level of uncertainty and speculative nature of the company's prospects despite the recent 13% stock price increase.

Key Decisions for Investors

• Investors should view the mixed ALTO-203 results as non-critical to the core investment thesis, instead focusing on catalysts from the broader and late-stage pipeline, including the newly acquired ALTO-207.
• The primary risk factor to monitor is the company's rapid cash burn rate relative to its clinical development timelines, even with its current strong liquidity position.
• Given the validation of the EEG biomarker strategy in the ALTO-203 trial, future trial designs incorporating this biomarker for patient selection should be considered a key potential de-risking event for the pipeline.